Upjohn price increases
Prices to wholesalers of the anxiolytic Xanax and hypnotic Halcion raised 7%, representing the second round of price hikes for the two benzodiazepine products this year; in February Upjohn raised prices for the two products by about 14%. In addition, Upjohn is also increasing prices for Micronase and the NSAID Ansaid by 6%. The price increases appear to be a response to flattening sales volume. In the second quarter, Upjohn reported a decline in sales of Xanax, Halcion and Micronase. Corporate sales increased only 2% in the quarter.
You may also be interested in...
In this week’s podcast, Medtech Insight's managing editor Marion Webb has an update from the virtual HLTH panel discussions on telehealth and robotics. Deputy editor Reed Miller discusses trial results from Boston Scientific’s next-generation Accurate neo2 self-expanding aortic valve presented during the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.